JP2018512401A - Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用 - Google Patents

Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用 Download PDF

Info

Publication number
JP2018512401A
JP2018512401A JP2017548089A JP2017548089A JP2018512401A JP 2018512401 A JP2018512401 A JP 2018512401A JP 2017548089 A JP2017548089 A JP 2017548089A JP 2017548089 A JP2017548089 A JP 2017548089A JP 2018512401 A JP2018512401 A JP 2018512401A
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
acid sequence
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017548089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512401A5 (https=
Inventor
シンシア ランダー
シンシア ランダー
コリーン ブロフィー
コリーン ブロフィー
キャリン ピーターソン
キャリン ピーターソン
アンドリュー ルバー
アンドリュー ルバー
Original Assignee
モイライ マトリックス インコーポレイテッド
モイライ マトリックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モイライ マトリックス インコーポレイテッド, モイライ マトリックス インコーポレイテッド filed Critical モイライ マトリックス インコーポレイテッド
Publication of JP2018512401A publication Critical patent/JP2018512401A/ja
Publication of JP2018512401A5 publication Critical patent/JP2018512401A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2017548089A 2015-03-12 2016-03-10 Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用 Pending JP2018512401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562132374P 2015-03-12 2015-03-12
US62/132,374 2015-03-12
PCT/US2016/021843 WO2016145234A2 (en) 2015-03-12 2016-03-10 Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same

Publications (2)

Publication Number Publication Date
JP2018512401A true JP2018512401A (ja) 2018-05-17
JP2018512401A5 JP2018512401A5 (https=) 2019-04-25

Family

ID=56880599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017548089A Pending JP2018512401A (ja) 2015-03-12 2016-03-10 Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用

Country Status (13)

Country Link
US (1) US9999655B2 (https=)
EP (1) EP3268022A4 (https=)
JP (1) JP2018512401A (https=)
KR (1) KR20170125090A (https=)
CN (1) CN107921082A (https=)
AU (1) AU2016229017A1 (https=)
BR (1) BR112017019343A2 (https=)
CA (1) CA2978941A1 (https=)
HK (1) HK1249433A1 (https=)
MX (1) MX2017011633A (https=)
RU (1) RU2017135072A (https=)
SG (1) SG11201707281QA (https=)
WO (1) WO2016145234A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023551798A (ja) * 2020-11-18 2023-12-13 ロンザ・ベンド・インコーポレーテッド 血管新生阻害剤を含む吸入可能な乾燥粉末製剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102827A1 (en) * 2016-12-04 2018-06-07 Expression Pathology, Inc. Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy
US11408887B2 (en) 2017-05-22 2022-08-09 The National Institute for Biotechnology in the Negev Ltd. Biomarkers for diagnosis of lung cancer
US10952799B2 (en) 2017-05-31 2021-03-23 Covidien Lp Systems and methods for navigational bronchoscopy and selective drug delivery
US20190134153A1 (en) * 2017-06-12 2019-05-09 Moerae Matrix, Inc. Immunomodulatory effect of inhaled kinase inhibitor peptides in lung
CN112334150B (zh) * 2018-06-12 2025-11-18 日内瓦大学 肽蛋白激酶c抑制剂及其用途
US11195062B2 (en) 2018-11-15 2021-12-07 Nantomics, Llc Classification based on characterization analysis methods and systems
EP4004548B1 (en) 2019-07-29 2026-01-14 Yeda Research and Development Co. Ltd Methods of treating and diagnosing lung cancer
CN113261532A (zh) * 2020-02-17 2021-08-17 中山大学 一种肺癌动物模型的构建方法
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
EP4608401A2 (en) * 2022-10-27 2025-09-03 Bristol-Myers Squibb Company Mk2 inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535508A (ja) * 2007-08-07 2010-11-25 パデュー リサーチ ファンデイション キナーゼ阻害薬およびその使用
EP2617431A2 (en) * 2007-01-10 2013-07-24 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
JP2014533235A (ja) * 2011-04-12 2014-12-11 モイライ マトリックス インコーポレイテッド 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE733059T1 (de) 1993-12-09 1997-08-28 Univ Jefferson Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
DE60026982T2 (de) 1999-04-05 2006-11-16 Mannkind Corp., Danbury Verfahren zur bildung von feinem pulver
DK1808438T3 (da) 1999-06-29 2014-10-27 Mannkind Corp Rensning og stabilisering af peptid og proteiner i lægemidler
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
BRPI0514410A (pt) 2004-08-23 2008-06-10 Mannkind Corp fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (https=) 2006-02-22 2015-07-10 Mannkind Corp
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
CA2744104C (en) 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20130115256A1 (en) 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
US10105356B2 (en) * 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP3467124A1 (en) * 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US20140072613A1 (en) 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617431A2 (en) * 2007-01-10 2013-07-24 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
JP2010535508A (ja) * 2007-08-07 2010-11-25 パデュー リサーチ ファンデイション キナーゼ阻害薬およびその使用
JP2014533235A (ja) * 2011-04-12 2014-12-11 モイライ マトリックス インコーポレイテッド 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J BIOL CHEM., 2007, VOL.282 NO.6, P.3507-3519, JPN6020008059, ISSN: 0004225098 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023551798A (ja) * 2020-11-18 2023-12-13 ロンザ・ベンド・インコーポレーテッド 血管新生阻害剤を含む吸入可能な乾燥粉末製剤

Also Published As

Publication number Publication date
SG11201707281QA (en) 2017-10-30
MX2017011633A (es) 2017-11-02
US9999655B2 (en) 2018-06-19
EP3268022A4 (en) 2018-11-21
US20160263187A1 (en) 2016-09-15
CN107921082A (zh) 2018-04-17
EP3268022A2 (en) 2018-01-17
CA2978941A1 (en) 2016-09-15
RU2017135072A (ru) 2019-04-10
HK1249433A1 (zh) 2018-11-02
RU2017135072A3 (https=) 2019-09-30
AU2016229017A1 (en) 2017-09-28
WO2016145234A2 (en) 2016-09-15
WO2016145234A3 (en) 2016-11-03
KR20170125090A (ko) 2017-11-13
BR112017019343A2 (pt) 2018-05-02

Similar Documents

Publication Publication Date Title
JP2018512401A (ja) Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用
JP6031510B2 (ja) 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法
JP2018501201A (ja) 異常な線維芽細胞増殖および細胞外マトリックス沈着を特徴とする疾患、状態、またはプロセスを予防または処置するための組成物および方法
JP6655547B2 (ja) 慢性肺移植片機能不全（ｃｌａｄ）および特発性肺線維症（ｉｐｆ）を予防または処置するための組成物および方法
US20180194817A1 (en) Compositions and methods for preventing or treating diseases, conditions or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
JP2018502860A (ja) Ｍｋ２阻害ペプチド製剤
US20190022176A1 (en) Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
HK1194983B (en) Compositions and methods for preventing or treating pulmonary fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200514

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201102